Prognostic impact of autophagy biomarkers for cutaneous melanoma

Frontiers in Oncology

Volumn 6, Issue NOV, 2016, Pages

  Tang, Diana Y L ^a,b   Ellis, Robert A ^a   Lovat, Penny E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Ambra1; Autophagy biomarkers; Malignant melanoma; P62; Prognostic biomarkers

Indexed keywords

AUTOPHAGY RELATED PROTEIN 8 FAMILY; BECLIN 1; MITOGEN ACTIVATED PROTEIN KINASE; SEQUESTOSOME 1; UNCLASSIFIED DRUG;

AUTOPHAGY; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL VACUOLE; CLINICAL OUTCOME; CUTANEOUS MELANOMA; ELECTRON MICROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MORBIDITY; MORTALITY; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR INVASION;

EID: 85006356575     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00236     Document Type: Short Survey

References (32)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol (2004) 150(2):179-85. doi:10.1111/j.1365-2133.2004.05708.x
2. Cichorek M, Wachulska M, Stasiewicz A, Tyminska A. Skin melanocytes: biology and development. Postepy Dermatol Alergol (2013) 30(1):30-41. doi:10.5114/pdia.2013.33376
3. Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, et al. Biomarkers in melanoma. Ann Oncol (2009) 20(Suppl 6):vi8-13. doi:10.1093/annonc/mdp251
4. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol (2005) 2(8):416-22. doi:10.1038/ncponc0252
5. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 101(7):452-74. doi:10.1093/jnci/djp038
6. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 27(36):6199-206. doi:10.1200/JCO.2009.23.4799
7. Checinska A, Soengas MS. The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy. Pigment Cell Melanoma Res (2011) 24(6):1116-32. doi:10.1111/j.1755-148X.2011.00927.x
8. Corazzari M, Fimia GM, Lovat P, Piacentini M. Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications. Semin Cancer Biol (2013) 23(5):337-43. doi:10.1016/j.semcancer.2013.07.001
9. Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol (2009) 335:1-32. doi:10.1007/978-3-642-00302-8_1
10. Mathew R, White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev (2011) 21(1):113-9. doi:10.1016/j.gde.2010.12.008
11. Ma XH, Piao S, Wang D, McAfee QW, Nathanson KL, Lum JJ, et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res (2011) 17(10):3478-89. doi:10.1158/1078-0432.CCR-10-2372
12. Armstrong JL, Corazzari M, Martin S, Pagliarini V, Falasca L, Hill DS, et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res (2011) 17(8):2216-26. doi:10.1158/1078-0432.CCR-10-3003
13. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther (2011) 10(3):385-94. doi:10.1158/1535-7163.MCT-10-0799
14. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-54. doi:10.1038/nature00766
15. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene (2003) 22(20):3138-51. doi:10.1038/sj.onc.1206454
16. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev (2005) 24(1):165-83. doi:10.1007/s10555-005-5865-1
17. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol (2011) 164(4):776-84. doi:10.1111/j.1365-2133.2010.10185.x
18. Maddodi N, Huang W, Havighurst T, Kim K, Longley BJ, Setaluri V. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol (2010) 130(6):1657-67. doi:10.1038/jid.2010.26
19. Corazzari M, Rapino F, Ciccosanti F, Giglio P, Antonioli M, Conti B, et al. Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma. Cell Death Differ (2015) 22(6):946-58. doi:10.1038/cdd.2014.183
20. Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol (2008) 445:77-88. doi:10.1007/978-1-59745-157-4_4
21. Lazova R, Klump V, Pawelek J. Autophagy in cutaneous malignant melanoma. J Cutan Pathol (2010) 37(2):256-68. doi:10.1111/j.1600-0560.2009.01359.x
22. Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res (2012) 18(2):370-9. doi:10.1158/1078-0432.CCR-11-1282
23. Miracco C, Cevenini G, Franchi A, Luzi P, Cosci E, Mourmouras V, et al. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol (2010) 41(4):503-12. doi:10.1016/j.humpath.2009.09.004
24. Sivridis E, Koukourakis MI, Mendrinos SE, Karpouzis A, Fiska A, Kouskoukis C, et al. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. Melanoma Res (2011) 21(3):188-95. doi:10.1097/CMR.0b013e328346612c
25. Hara Y, Nakamura M. Overexpression of autophagy-related beclin-1 in advanced malignant melanoma and its low expression in melanoma-in-situ. Eur J Dermatol (2012) 22(1):128-9. doi:10.1684/ejd.2011.1562
26. Ellis RA, Horswell S, Ness T, Lumsdon J, Tooze SA, Kirkham N, et al. Prognostic impact of p62 expression in cutaneous malignant melanoma. J Invest Dermatol (2014) 134(5):1476-8. doi:10.1038/jid.2013.497
27. Armstrong JL, Hill DS, McKee CS, Hernandez-Tiedra S, Lorente M, Lopez-Valero I, et al. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol (2015) 135(6):1629-37. doi:10.1038/jid.2015.45
28. Fimia GM, Di Bartolomeo S, Piacentini M, Cecconi F. Unleashing the Ambra1-Beclin 1 complex from dynein chains: Ulk1 sets Ambra1 free to induce autophagy. Autophagy (2011) 7(1):115-7. doi:10.4161/auto.7.1.14071
29. Hamanaka RB, Chandel NS. Mitochondrial metabolism as a regulator of keratinocyte differentiation. Cell Logist (2013) 3(1):e25456. doi:10.4161/cl.25456
30. Hamanaka RB, Glasauer A, Hoover P, Yang S, Blatt H, Mullen AR, et al. Mitochondrial reactive oxygen species promote epidermal differentiation and hair follicle development. Sci Signal (2013) 6(261):ra8. doi:10.1126/scisignal.2003638
31. Vazquez P, Arroba AI, Cecconi F, de la Rosa EJ, Boya P, de Pablo F. Atg5 and Ambra1 differentially modulate neurogenesis in neural stem cells. Autophagy (2012) 8(2):187-99. doi:10.4161/auto.8.2.18535
32. Tang D, Greenwood A, Carling E, Horswell S, Lovat P, Ellis RA. Epidermal AMBRA1 and Loricrin as Novel Prognostic Biomarkers for Melanoma. BSID Annual Meeting 2016. Dundee, Scotland: Wiley-Blackwell (2016).